# A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants

> **NCT02555124** · PHASE1 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-42847922, 5 mg
- **DRUG:** JNJ-42847922, 20 mg
- **DRUG:** JNJ-42847922, 40 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02555124
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-12
- **Primary completion:** 2015-10-31
- **Final completion:** 2015-10-31
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02555124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02555124, "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02555124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*